Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic
Kelly K. Bree(The University of Texas MD Anderson Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Patrick J. Hensley(University of Kentucky), Mary E. Westerman(The University of Texas MD Anderson Cancer Center), Nathan A. Brooks(Eli Lilly (United States)), Yu Shen(The University of Texas MD Anderson Cancer Center), Wei Qiao(The University of Texas MD Anderson Cancer Center), Andrea Kokorovic(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 14
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
What Is the Significance of Variant Histology in Urothelial Carcinoma?
|European Urology Focus|2019|251
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
|Nature Reviews Urology|2022|196